George Church
George Church

Dr. George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), co-author of 515 papers, 143 patent publications & the book "Regenesis". Dr. Church has developed methods used for the first genome sequence (1994) and million-fold cost reductions since (via fluor-NGS & nanopores), plus barcoding, DNA assembly from chips, genome editing, writing, and recoding. He also co-initiated BRAIN Initiative (2011) & Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005: world's open-access personal precision medicine datasets); machine learning for protein engineering, tissue reprogramming, organoids, xeno-transplanation, in situ 3D DNA, RNA, protein imaging.


George Church
Carl June

Dr. June is internationally recognized for his role in pioneering CAR T-cell therapy, which led to the first FDA-approved personalized cellular therapy for children and young adults with a type of blood cancer called acute lymphoblastic leukemia in 2017. This monumental achievement has since spurred five additional approvals of the technique for other blood cancers.

Dr. June, director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, has authored more than 500 publications and has received numerous prestigious awards. Among his most recent accolades is the 2024 Breakthrough Prize in Life Sciences. His remarkable recognitions also includes the AACR Award for Lifetime Achievement in Cancer Research, the Keio Medical Science Prize, the Dan David Prize, and the William B. Coley Award, among other notable distinctions.


George Church
David Liu

The notable contributions of Dr. Liu’s laboratory include the invention of two precise gene editing methods that do not require double-stranded DNA breaks: base editing, a groundbreaking method for the precise introduction of single-letter gene edits, and prime editing, a highly versatile genome editing technology that installs precise substitutions, insertions, or deletions and is inherently resistant to off-target editing. His research through the use of phage-assisted continuous evolution (PACE) has paved the way for the discovery of proteins with novel therapeutic potential, and his pioneering of DNA-encoded small-molecule libraries laid a foundation for the current use of DNA-encoded libraries to accelerate drug discovery.

Dr. Liu, Professor at Harvard University, Broad Institute, and Howard Hughes Medical Institute, holds numerous prestigious awards and has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. His over 258 publications and more than 105 issued U.S. patents demonstrate his commitment and influence in the fields of chemistry, biology, and therapeutics.